CLINICAL TRIALS PROFILE FOR IBODUTANT
✉ Email this page to a colleague
Clinical Trials for Ibodutant
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00761007 ↗ | Ibodutant for Relief of Irritable Bowel Syndrome (IRIS) | Completed | Menarini Group | Phase 2 | The purpose of the study is to evaluate the benefit of treatment with oral dose of Ibodutant (code: MEN 15596) on IBS symptoms and the safety and tolerability of this therapy. |
NCT01303224 ↗ | Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D) | Completed | Menarini Group | Phase 2 | Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial aims at the evaluation of the efficacy and safety of the neurokinin type 2 receptor antagonist Ibodutant in improving IBS-D symptoms. |
NCT02107196 ↗ | 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Completed | Menarini Group | Phase 3 | Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial aims at the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as compared to placebo in women with IBS-D over a 12-week treatment period. |
NCT02120027 ↗ | 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Terminated | Menarini Group | Phase 3 | Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial aims at the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as compared to placebo in women with IBS-D over a 24-week treatment period. |
NCT02320318 ↗ | 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Withdrawn | Menarini Group | Phase 3 | Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. The aim of this trial is the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as compared to placebo in women with IBS-D over a 12-week treatment period. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Ibodutant
Condition Name
Clinical Trial Locations for Ibodutant
Trials by Country
Clinical Trial Progress for Ibodutant
Clinical Trial Phase
Clinical Trial Sponsors for Ibodutant
Sponsor Name